Safety and Immunogenicity of MRNAs Encoding HIV Immunogens (eOD-GT8 60mer, Core-g28v2 60mer, N332-GT5 Gp151) in Adult Participants Without HIV and in Overall Good Health in South Africa (HVTN 317)
- Conditions
- HIV Infections
- Interventions
- Registration Number
- NCT06694753
- Lead Sponsor
- HIV Vaccine Trials Network
- Brief Summary
The purpose of this study is to evaluate the safety and immunogenicity of mRNAs encoding HIV immunogens (eOD-GT8 60mer, core-g28v2 60mer, N332-GT5 gp151) in adult participants without HIV and in overall good health in South Africa.
- Detailed Description
This study will evaluate the safety and immunogenicity of 3 experimental HIV vaccines in adult participants without HIV and in overall good health in South Africa. The study vaccines are called mRNA-1645-eODGT8, mRNA-1645-CoreG28v2 and mRNA-1645-N332GT5.
The study will be conducted in two parts (Part A and B). Part A will include two Cohorts, each with 2 groups: Cohort 1A Group 1, Cohort 1A Group 2, Cohort 2A Group 3, and Cohort 2A Group 4. Part B will include two Cohorts, each with 2 groups: Cohort 1B Group 5, Cohort 1B Group 6, Cohort 2B Group 7, and Cohort 2B Group 8.
Participants in Part A Cohort 1A will be randomly assigned to receive mRNA-1645-eODGT8 followed by mRNA-1645-CoreG28v2 or to receive placebo. Participants in Part A Cohort 2A will be randomly assigned to receive two doses of the mRNA-1645-N332GT5 vaccine or to receive placebo. Cohorts 1A and 2A in Part A will be enrolled concurrently, and randomization to study product or placebo will take place in each cohort. Depending on their group, participants will receive 10 mcg of mRNA-1645-eODGT8, mRNA-1645-N332GT5 or Placebo by injection at Week 0 and 10 mcg of mRNA-1645-CoreG28v2, mRNA-1645-N332GT5, or Placebo at Week 8.
Participants in Part B Cohort 1B will be randomly assigned to receive an increased dose of the mRNA-1645-eODGT8 and mRNA-1645-CoreG28v2 vaccine or to receive placebo. Participants in Part B Cohort 2B will be randomly assigned to receive an increased dose of the mRNA-1645-N332GT5 vaccine or to receive placebo. Cohorts 1B and 2B in Part B will be enrolled concurrently, and randomization to study product or placebo will take place in each cohort. Depending on their group, participants will receive 30 mcg of mRNA-1645-eODGT8, mRNA-1645-N332GT5 or Placebo by injection at Week 0 and 30 mcg of mRNA-1645-CoreG28v2, mRNA-1645-N332GT5, or Placebo at Week 8.
Additional study visits will occur at Weeks 2, 7.5, 10, 15.5, and 24. Study visits may include physical examinations, medical history, vaccine injections, blood and urine collection, electrocardiogram, leukapheresis, lymph node cell collection, pregnancy test, HIV testing, risk reduction counseling, and questionnaires.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 96
-
Demonstrates an understanding of the study and is able and willing to complete the informed consent process.
-
18 to 55 years old, inclusive, on day of enrollment.
-
Available for clinic follow-up through the last clinic visit.
-
Willingness to undergo FNA and leukapheresis.
-
Agrees not to enroll in another study of an investigational agent during participation in the trial. If a potential participant is already enrolled in another clinical trial, approvals from the other trial sponsor and the HVTN 317/DESIIGN001 PSRT are required prior to enrollment into HVTN 317/DESIIGN001.
-
In good general health according to the clinical judgment of the site investigator.
-
Physical examination and laboratory results without clinically significant findings that would interfere with assessment of safety or reactogenicity in the clinical judgment of the site investigator.
-
Assessed by clinical staff as having a low likelihood of acquiring HIV, agrees to discuss their potential for HIV acquisition, agrees to prevention counseling, and agrees to avoid behaviors associated with a higher likelihood of acquiring HIV through the final study visit. "Low likelihood" may include persons stably taking pre-exposure prophylaxis (PrEP).
-
Hemoglobin (Hgb):
- 12.0 g/dL for AFAB volunteers
- 13.0 g/dL for cisgender AMAB volunteers or for volunteers who have been on masculinizing hormone therapy for more than 6 consecutive months
- 12.0 g/dL for AMAB volunteers who have been on feminizing hormone therapy for more than 6 consecutive months For volunteers who have been on gender-affirming hormone therapy for less than 6 consecutive months, determine Hgb eligibility based on their sex assigned at birth.
-
White blood cell (WBC) count = 2,500 to 12,000/mm3.
-
Platelets = 125,000 to 550,000/mm3.
-
Alanine aminotransferase (ALT) <2.5× upper limit of institutional reference range.
-
Serum creatinine ≤1.1× upper limit of normal (ULN) based on the institutional normal range.
-
Systolic blood pressure of 90 to <140 mmHg and diastolic blood pressure of 50 to <90 mmHg at screening visit. The average blood pressure between the screening visit and the enrollment visit must be below 140 mmHg systolic and 90 mmHg diastolic. A single measurement ≥160 systolic mmHg or 100 mmHg diastolic during the current study evaluation is exclusionary.
-
Negative HIV test results by one of the following options:
A negative European Conformity (CE)-marked enzyme immunoassay (EIA) A chemiluminescent microparticle immunoassay (CMIA) A negative result on 2 HIV rapid tests (one of these rapid tests must be CE-marked)
- Negative for anti-Hepatitis C virus (HCV) Abs (anti-HCV) or negative HCV nucleic acid test (NAT) if anti-HCV Abs are detected.
- Negative for Hepatitis B surface antigen (HBsAg).
For volunteers AFAB or assigned intersex at birth who are capable of becoming pregnant (hereafter referred to as "persons of pregnancy potential"):
Must agree to use effective means of contraception from at least 21 days prior to enrollment through 8 weeks after their last scheduled vaccination timepoint.
Must have a negative beta human chorionic gonadotropin (β-HCG) pregnancy test (urine or serum) on day of enrollment.
Note: Persons who are NOT of pregnancy potential due to total hysterectomy or bilateral oophorectomy or menopause (no menses for ≥1 year) are not required to undergo pregnancy testing.
- Volunteers AFAB or assigned intersex at birth must agree to not seek pregnancy through alternative methods, such as oocyte retrieval, artificial insemination, or in vitro fertilization from at least 21 days prior to enrollment through 8 weeks after their last scheduled vaccination timepoint.
- Volunteer who is nursing or pregnant.
- Body mass index (BMI) ≥ 40. Enrollment of individuals with BMI ≥ 40, whom the site investigator assesses are in good health, may be considered by the PSRT.
- Diabetes mellitus (DM). Type 2 DM controlled with diet alone (and confirmed by HgbA1c ≤ 7% within the last 6 months) or a history of isolated gestational diabetes are not exclusionary. Enrollment of individuals with Type 2 DM that is well controlled on hypoglycemic agent(s) may be considered by the PSRT on a case-by-case basis, provided that the HgbA1c is ≤ 8% within the last 6 months (sites may draw these at screening).
- Previous or current recipient of an investigational HIV vaccine (previous placebo/control recipients are not excluded).
- Receipt of non-HIV investigational vaccine(s) received within the last 1 year. Exceptions include vaccines that have subsequently undergone licensure or Emergency Use Authorization (EUA) by the FDA or World Health Organization (WHO) Emergency Use Listing (EUL), or if outside the US, by the national Regulatory Authority (RA) authorizing this clinical trial.
- Congenital or acquired immunodeficiency, including systemic medication use likely to impair immune response to vaccine in the opinion of the site investigator, such as glucocorticoid use, ≥ prednisone 10 mg/day within 3 months prior to enrollment.
- Blood products or immunoglobulin within 16 weeks prior to enrollment; receipt of immunoglobulin within 16 weeks prior to enrollment requires PSRT approval.
- Previous receipt of VRC01 or VRC07-523LS monoclonal antibody (mAb).
- Receipt of any vaccine within 4 weeks prior to enrollment or planned receipt within 4 weeks of investigational vaccine administration.
- History of myocarditis and/or pericarditis.
- Potentially immune-mediated disease, including but not limited to thyroid disease, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, celiac disease, seronegative inflammatory arthritis, systemic sclerosis, and type 1 diabetes.
- History of or active severe skin conditions, including but not limited to cutaneous mastocytosis, psoriasis, atopic dermatitis, lichen planus, hidradenitis suppurativa, bullous pemphigoid, and urticarial vasculitis.
- Systemic or local conditions with urticaria as a manifestation, including urticarial vasculitis, maculo-papular cutaneous mastocytosis (formerly urticaria pigmentosa), mast cell activation syndrome, Gleich's syndrome (epiosodic angiodema with eosinophilia), Well's syndrome (granulomatous dermatitis with eosinophilia/eosinophilic cellulitis), bullous pemphigoid, or adult-onset Still's disease.
- Receipt of antigen-based immunotherapy.
- Receipt of investigational research agents with a half-life of 7 or fewer days within 4 weeks prior to enrollment. If a potential participant has received investigational agents with a half-life of more than 7 days (or unknown half-life) within the past year, PSRT approval is required for enrollment.
- History of serious reaction (eg, hypersensitivity, anaphylaxis) to any vaccine or component of the study-vaccine regimen.
- Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema.
- History of urticaria and/or dermatographism and/or angioedema.
- History of atopy (diagnosed or confirmed by a clinician).
- Bleeding disorder diagnosed by a clinician that would make study procedures a contraindication.
- History of seizure(s) within the past 3 years. Also exclude if volunteer has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.
- Asplenia or functional asplenia.
- Any other chronic or clinically significant condition that, in the clinical judgment of the investigator, would jeopardize the safety or rights of the study participant, including but not limited to: clinically significant forms of substance use or alcohol use disorder(s), serious psychiatric disorders, any suicide attempt within the past 1 year (if between 1 and 2 years, consult PSRT for approval), or cancer that, in the clinical judgment of the site investigator, has potential for recurrence (excluding basal cell carcinoma).
- Asthma (diagnosed or confirmed by a clinician).
- History of allergy to local anesthetic (Novocaine, Lidocaine).
- Investigator concern for difficulty with venous access based on clinical history and physical examination. For example, persons with a history of intravenous drug use or substantial difficulty with previous blood draws.
- Has donated ≥450 mL of blood products within 28 days prior to the Screening Visit or plans to donate blood products within 28 days post study injection.
- Is working or has worked as study personnel or is an immediate family member or house member of study personnel, study site staff, or Sponsor personnel.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Cohort 1B Group 5: mRNA-1645-eODGT8 + mRNA-1645-CoreG28v2 mRNA-1645-CoreG28v2 Participants will receive one injection of 30 mcg mRNA-1645-eODGT8 to be administered as a 0.5 mL IM injection into the deltoid at Week 0 and one injection of 30 mcg mRNA-1645-CoreG28v2 to be administered as a 0.5 mL IM injection into the deltoid at Week 8. Cohort 2A Group 4: Placebo Placebo Participants will receive 0.9% sodium chloride to be administered as a 0.5-mL IM injection into the deltoid at Week 0 and Week 8. Cohort 1A Group 1: mRNA-1645-eODGT8 + mRNA-1645-CoreG28v2 mRNA-1645-eODGT8 Participants will receive one injection of 10 mcg mRNA-1645-eODGT8 to be administered as a 0.5 mL IM injection into the deltoid at Week 0 and one injection of 10 mcg mRNA-1645-CoreG28v2 to be administered as a 0.5 mL IM injection into the deltoid at Week 8. Cohort 1A Group 1: mRNA-1645-eODGT8 + mRNA-1645-CoreG28v2 mRNA-1645-CoreG28v2 Participants will receive one injection of 10 mcg mRNA-1645-eODGT8 to be administered as a 0.5 mL IM injection into the deltoid at Week 0 and one injection of 10 mcg mRNA-1645-CoreG28v2 to be administered as a 0.5 mL IM injection into the deltoid at Week 8. Cohort 1A Group 2: Placebo Placebo Participants will receive 0.9% sodium chloride to be administered as a 0.5-mL IM injection into the deltoid at Weeks 0 and 8. Cohort 2A Group 3: mRNA-1645-N332GT5 mRNA-1645-N332GT5 Participants will receive 10 mcg of mRNA-1645-N332GT5 to be administered as a 0.5 mL IM injection into the deltoid at Weeks 0 and 8. Cohort 1B Group 5: mRNA-1645-eODGT8 + mRNA-1645-CoreG28v2 mRNA-1645-eODGT8 Participants will receive one injection of 30 mcg mRNA-1645-eODGT8 to be administered as a 0.5 mL IM injection into the deltoid at Week 0 and one injection of 30 mcg mRNA-1645-CoreG28v2 to be administered as a 0.5 mL IM injection into the deltoid at Week 8. Cohort 1B Group 6: Placebo Placebo Participants will receive 0.9% sodium chloride to be administered as a 0.5-mL IM injection into the deltoid at Week 0 and Week 8. Cohort 2B Group 7: mRNA-1645-N332GT5 mRNA-1645-N332GT5 Participants will receive 30 mcg of mRNA-1645-N332GT5 to be administered as a 0.5 mL IM injection into the deltoid at Weeks 0 and 8. Cohort 2B Group 8: Placebo Placebo Participants will receive 0.9% sodium chloride to be administered as a 0.5-mL IM injection into the deltoid at Week 0 and Week 8.
- Primary Outcome Measures
Name Time Method Number of participants reporting local reactogenicity signs and symptoms Measured a minimum of 7 days following receipt of any study vaccination Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[March 2017\]
Number of participants reporting systemic reactogenicity signs and symptoms Measured for a minimum of 7 days following receipt of any study vaccination Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[March 2017\]
Number of AEs leading to early participant withdrawal or permanent discontinuation Measured through week 24 (16 weeks after the second and final vaccination). Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[March 2017\]
Number of SAEs Measured through week 24 (16 weeks after the second and final vaccination). Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[March 2017\]
Number of medically attended adverse event (MAAEs) Measured through week 24 (16 weeks after the second and final vaccination). Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[March 2017\]
Number of AESIs Measured through week 24 (16 weeks after the second and final vaccination). If a participant develops chronic urticaria, an AESI, they will be followed up through week 48 (40 weeks after the final vaccination) if indicated. Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[March 2017\]
Number of AEs Measured through 30 days after any receipt of study vaccination. Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[March 2017\]
Proportion of participants with VRC01- or BG18-class IgG B cells Measured at baseline (at Week 0), 7.5 weeks post 1st vaccination (at Week 7.5), and 7.5 weeks post 2nd vaccination (at Week 15.5) Determined by B-cell phenotyping and BCR sequencing.
Frequency of VRC01- or BG18-class B cells among IgG+ B cells in PBMCs or in germinal centers Measured at baseline (at Week 0), 7.5 weeks post 1st vaccination (at Week 7.5), and 7.5 weeks post 2nd vaccination (at Week 15.5) Determined by B-cell phenotyping and BCR sequencing
- Secondary Outcome Measures
Name Time Method Response rate of serum IgG binding Abs Measured at baseline (at Week 0), 2 weeks post 1st vaccination (at Week 2), 7.5 weeks post 1st vaccination (at Week 7.5), 2 weeks post 2nd vaccination (at Week 10), and 7.5 weeks post 2nd vaccination (at Week 15.5) Assessed by BAMA
Magnitude of serum IgG binding Abs Measured at baseline (at Week 0), 2 weeks post 1st vaccination (at Week 2), 7.5 weeks post 1st vaccination (at Week 7.5), 2 weeks post 2nd vaccination (at Week 10), and 7.5 weeks post 2nd vaccination (at Week 15.5) Assessed by BAMA
Trial Locations
- Locations (8)
Setshaba Research Centre CRS
🇿🇦Soshanguve, Gauteng, South Africa
Soweto HVTN CRS
🇿🇦Soweto, Gauteng, South Africa
Chatsworth CRS
🇿🇦Chatsworth, Kwa Zulu Natal, South Africa
CAPRISA eThekwini CRS
🇿🇦Durban, Kwa Zulu Natal, South Africa
Isipingo CRS
🇿🇦Isipingo Rail, Kwa Zulu Natal, South Africa
Klerksdorp CRS
🇿🇦Klerksdorp, North West Province, South Africa
Emavundleni CRS
🇿🇦Cape Town, Western Cape, South Africa
Groote Schuur HIV CRS
🇿🇦Cape Town, Western Cape, South Africa